Recent Finacing
Recent Raise
Pieris develops Anticalin®-based biotherapeutics for oncology and pulmonary diseases, advancing inhalable PRS-220 for SARS‑CoV‑2–related lung injury and post‑COVID fibrosis from clinical-stage programs in Hallbergmoos, Germany.
